RU2322978C2 - Фармацевтические композиции, содержащие частичный агонист 5ht4 - Google Patents

Фармацевтические композиции, содержащие частичный агонист 5ht4 Download PDF

Info

Publication number
RU2322978C2
RU2322978C2 RU2004122631/15A RU2004122631A RU2322978C2 RU 2322978 C2 RU2322978 C2 RU 2322978C2 RU 2004122631/15 A RU2004122631/15 A RU 2004122631/15A RU 2004122631 A RU2004122631 A RU 2004122631A RU 2322978 C2 RU2322978 C2 RU 2322978C2
Authority
RU
Russia
Prior art keywords
amount
composition according
tegaserod
composition
mixture
Prior art date
Application number
RU2004122631/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2004122631A (ru
Inventor
Жером ОБЕР (FR)
Жером ОБЕР
Кристиан ВИТЗЛИНГ (FR)
Кристиан ВИТЗЛИНГ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2004122631A publication Critical patent/RU2004122631A/ru
Application granted granted Critical
Publication of RU2322978C2 publication Critical patent/RU2322978C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2004122631/15A 2001-12-21 2002-12-20 Фармацевтические композиции, содержащие частичный агонист 5ht4 RU2322978C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01403339.3 2001-12-21
EP01403339A EP1321142A1 (en) 2001-12-21 2001-12-21 Solid pharmaceutical composition for oral administration of Tegaserod

Publications (2)

Publication Number Publication Date
RU2004122631A RU2004122631A (ru) 2005-08-10
RU2322978C2 true RU2322978C2 (ru) 2008-04-27

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004122631/15A RU2322978C2 (ru) 2001-12-21 2002-12-20 Фармацевтические композиции, содержащие частичный агонист 5ht4

Country Status (31)

Country Link
US (2) US20050106236A1 (enExample)
EP (2) EP1321142A1 (enExample)
JP (1) JP4718776B2 (enExample)
KR (1) KR100980144B1 (enExample)
CN (1) CN100464749C (enExample)
AR (1) AR037937A1 (enExample)
AT (1) ATE320807T1 (enExample)
AU (1) AU2002361198B2 (enExample)
BR (1) BR0215148A (enExample)
CA (1) CA2470668C (enExample)
CO (1) CO5640102A2 (enExample)
CY (1) CY1105559T1 (enExample)
DE (1) DE60210139T2 (enExample)
DK (1) DK1458377T3 (enExample)
EC (1) ECSP105163A (enExample)
EG (1) EG24194A (enExample)
ES (1) ES2258171T3 (enExample)
HU (1) HU226589B1 (enExample)
IL (2) IL162451A0 (enExample)
MX (1) MXPA04006157A (enExample)
MY (1) MY139546A (enExample)
NO (1) NO20042779L (enExample)
NZ (1) NZ533585A (enExample)
PE (1) PE20030872A1 (enExample)
PL (1) PL369509A1 (enExample)
PT (1) PT1458377E (enExample)
RU (1) RU2322978C2 (enExample)
SI (1) SI1458377T1 (enExample)
TW (1) TWI260221B (enExample)
WO (1) WO2003053432A1 (enExample)
ZA (1) ZA200404467B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL200132B1 (pl) * 1998-08-21 2008-12-31 Novartis Ag Zastosowanie 3-(5-metoksy-1H-indol-3-ilometyleno)-N-pentylokarbazyimidoamidu
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004007105T2 (de) 2003-01-28 2008-02-28 Microbia Inc., Cambridge Zusammensetzung zur behandlung von gastrointestinalen störungen
WO2004085393A1 (en) * 2003-03-25 2004-10-07 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
WO2004104577A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
AR045081A1 (es) * 2003-07-24 2005-10-12 Novartis Ag Modificaciones estables de maleato de hidrogeno de tegaserod
PT1663182E (pt) 2003-09-12 2013-03-14 Amgen Inc Formulação de dissolução rápida de cinacalcet hcl
US20050165085A1 (en) * 2003-12-16 2005-07-28 Marioara Mendelovici Polymorphic forms of tegaserod base and salts thereof
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP3351248B1 (en) 2008-12-31 2021-06-09 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2880338A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
KR102287207B1 (ko) 2013-04-12 2021-08-09 알데릭스, 인코포레이티드 Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
EA036204B1 (ru) * 2015-10-16 2020-10-14 Нобел Илач Санайи Ве Тиджарет А.Ш. Фармацевтические композиции нилотиниба гидрохлорида
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Ｎｈｅ媒介性アンチポートの阻害薬
CN110267944B (zh) 2017-01-09 2024-03-08 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010526A2 (en) * 1998-08-21 2000-03-02 Novartis Ag New oral formulation for 5-ht4 agonists or antagonists
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
ATE220543T1 (de) * 1996-04-23 2002-08-15 Janssen Pharmaceutica Nv Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
DE60039357D1 (de) * 1999-08-03 2008-08-14 Lilly Icos Llc Pharmazeutische zusammensetzung enthaltend tadalafil

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010526A2 (en) * 1998-08-21 2000-03-02 Novartis Ag New oral formulation for 5-ht4 agonists or antagonists
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Фармацевтические и медико-биологические аспекты лекарств / Под ред. И.М.ПЕРЦЕВА. - Харьков: Издательство НФАУ, 1999, т.2, с.354. Технология и стандартизация лекарств / Под ред. В.П.Георгиевского. - Харьков: OOO «Рирег», 1996, т.1, с.562-564. *

Also Published As

Publication number Publication date
DE60210139D1 (de) 2006-05-11
CA2470668A1 (en) 2003-07-03
NZ533585A (en) 2006-04-28
KR100980144B1 (ko) 2010-09-03
IL162451A0 (en) 2005-11-20
JP4718776B2 (ja) 2011-07-06
ECSP105163A (es) 2010-07-30
AU2002361198A1 (en) 2003-07-09
NO20042779L (no) 2004-09-17
CO5640102A2 (es) 2006-05-31
AU2002361198B2 (en) 2006-06-08
SI1458377T1 (sl) 2006-08-31
EP1458377B1 (en) 2006-03-22
JP2005516946A (ja) 2005-06-09
RU2004122631A (ru) 2005-08-10
DK1458377T3 (da) 2006-06-12
ZA200404467B (en) 2006-05-31
KR20040066922A (ko) 2004-07-27
HUP0402492A3 (en) 2008-04-28
MY139546A (en) 2009-10-30
EG24194A (en) 2008-10-14
IL162451A (en) 2009-02-11
HU226589B1 (en) 2009-04-28
EP1458377A1 (en) 2004-09-22
TWI260221B (en) 2006-08-21
EP1321142A1 (en) 2003-06-25
WO2003053432A1 (en) 2003-07-03
US20090104263A1 (en) 2009-04-23
CN100464749C (zh) 2009-03-04
PE20030872A1 (es) 2003-11-24
PL369509A1 (en) 2005-04-18
MXPA04006157A (es) 2004-10-27
TW200410684A (en) 2004-07-01
CN1606438A (zh) 2005-04-13
HUP0402492A2 (hu) 2005-07-28
DE60210139T2 (de) 2006-08-17
US20050106236A1 (en) 2005-05-19
ES2258171T3 (es) 2006-08-16
AR037937A1 (es) 2004-12-22
PT1458377E (pt) 2006-07-31
CA2470668C (en) 2011-07-05
ATE320807T1 (de) 2006-04-15
BR0215148A (pt) 2004-10-19
CY1105559T1 (el) 2010-07-28

Similar Documents

Publication Publication Date Title
RU2322978C2 (ru) Фармацевтические композиции, содержащие частичный агонист 5ht4
CA2272586C (en) Rapidly disintegrable pharmaceutical composition
RU2456989C2 (ru) Твердые лекарственные формы, содержащие тадалафил
US5972381A (en) Solid solution of an antifungal agent with enhanced bioavailability
JPWO1998029137A1 (ja) 速崩壊性医薬組成物
US20100204292A1 (en) Pharmaceutical compositions comprising intra-and extra-granular fractions
EP0954288B1 (en) Solid solution of an antifungal agent with enhanced bioavailability
JP2012503613A (ja) コンパクト化シナカルセット
JP2010536798A (ja) 難溶性薬物の生体利用率を制御するための方法及び組成物
HU200924B (en) Process for producing pharmaceutical compositions comprising terfenadine
KR20080059212A (ko) 3-(2-디메틸아미노메틸 사이클로헥실) 페놀 지연 제형
EP2903593B1 (en) Tablet containing composite with cyclodextrin
US20050042279A1 (en) Pharmaceutical formulation comprising more than 15% tamoxifen
WO2023126973A1 (en) Stable pharmaceutical composition of elagolix
WO2020240505A1 (en) Immediate release fixed-dose combination of memantine and donepezil

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20121221